Civica Rx to Provide Major Long-Acting Insulin Cost Savings in 2026

Starting in January 2026, Civica Rx, a nonprofit drug manufacturing company, will launch its affordable insulin glargine. Insulin glargine is a type of long-acting basal insulin.. Brand names of insulin glargine include Lantus, Basaglar, Semglee,Rezvoglar, and Toujeo. For people with diabetes (PWD), long-acting basal insulins provide a steady, low-level insulin supply. Background insulins like this help with blood sugar regulation throughout the day.

In many diabetes management plans, long-acting insulins are used in combination with short-acting insulins. Short-acting insulins are administered at mealtime or to correct high blood sugar levels. For all people with type 1 diabetes (T1D) and some people with type 2 diabetes (T2D), using both insulin types is common practice.

Reducing the Burdens of Diabetes

Starting in 2026, a box of five Civica RX insulin pens will be available for a suggested out-of-pocket cost of no more than $55 at pharmacy counters across the U.S., regardless of insurance coverage. 

This could reduce the cost of long-acting insulin for millions of people. According to Healthline, prefilled insulin pens typically cost hundreds of dollars before insurance. 

Factors impacting the cost at the pharmacy counter mainly revolve around health insurance—whether someone with diabetes has it, whether they’ve met their deductible, whether their health insurance covers the insulin (a.k.a. whether it’s on the formulary), etc. 

Navigating insurance coverage can be complicated, and it’s best to contact your health insurance or healthcare team when you have questions.

Civica Rx is providing another option. The company stated that its pricing model differs from copay assistance programs, which PWD must register for and can change at any time.

Meaningful Steps Toward Affordable Insulin Access

In 2018, Civica Rx was established to address drug shortages and high prices associated with them, as well as to enhance the reliability of the drug supply chain.

In partnership with Biocon Biologics, the launch of this insulin will demonstrate Civica Rx’s commitment to addressing some of the most pressing healthcare challenges facing the nation today, like rationing insulin. According to the American Diabetes Association (ADA) and other studies, about one in four Americans ration insulin due to cost burdens and other barriers to access. Rationing insulin can result in serious complications for PWD and even death.

“This partnership marks a meaningful step forward in expanding access to essential insulins for patients across the United States,” said Shreehas Tamble, CEO and Managing Director, Biocon Biologics, Ltd.

This partnership was established to tackle the prescription drug affordability crisis, and in 2026, PWD will finally be able to enjoy the benefits of that effort.